LA22-radioimmunoconjugates (Welson/Peking University)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameLA22-radioimmunoconjugates (Welson/Peking University)
Drug Alias NamemAb-conjugated radioimmunotherapeutics (Welson/Peking University)177Lu-DTPA-LA22lutetium177-DOTA-LA22177Lu-DOTA-LA22
ClassificationRadiation-emitting products > Radioactive therapeutic agentBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate
Mechanisms of ActionEpidermal growth factor receptor erbB1 modulators
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesWelson Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWelson Pharmaceuticals IncPeking University
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A